Most patients with these problems—which can lead to permanent disability and death—developed symptoms within a day of receiving an initial infusion of Lemtrada, the agency said. In one patient, symptoms occurred three days after receiving the drug. (HealthDay)—A new warning has been added to the multiple sclerosis drug Lemtrada (alemtuzumab) after rare reports of patients suffering strokes and tears...